Dataset from A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of Two Fixed Doses (200 Mg, Or 400 Mg) Of DVS-233 SR In Adult Outpatients With Major Depressive Disorder

Primary Objective: To compare the antidepressant efficacy and safety of subjects receiving
DVS-233 SR versus subjects receiving placebo.

Secondary Objective: To assess the response of subjects receiving DVS-233 SR for the clinical
global evaluation, functionality, general wellbeing, pain, and absence of symptoms (Hamilton
Psychiatric Rating Scale for Depression, 17-item [HAM-D17] less than or equal to 7) versus
those subjects receiving placebo.